Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment
Metrics: PDF 546 views | Full Text 767 views | ?
María José Godoy-Calderón1,2, Eglys González-Marcano1,2, Jeismar Carballo2 and Ana Federica Convit1,2
1 Unidad Experimental de Inmunoterapia, Fundación Jacinto Convit, Caracas, Venezuela
2 Jacinto Convit World Organization, Inc., Palo Alto, CA, USA
|María José Godoy-Calderón,||email:||firstname.lastname@example.org|
Keywords: combination immunotherapies; cancer immunotherapy; breast cancer; autologous tumor cells vaccine; anti-PD-1
Received: May 29, 2019 Accepted: September 24, 2019 Published: November 12, 2019
Breast cancer therapies using checkpoints alone have not been highly effective. Based on previous experiences using the ConvitVax, an autologous tumor cells/bacillus Calmette-Guérin (BCG)/formalin-based vaccine, in breast cancer and the potential success of combined therapies, we sought to ascertain whether the ConvitVax combined with anti-PD-1 enhances the antitumor effect in a 4T1 breast cancer model. Animals received four weekly injections of either PBS (G1), ConvitVax (200 μg cell homogenate, 0.0625 mg BCG, 0.02% formalin) (G2), 50 μg anti-PD-1 (G3), or ConvitVax plus anti-PD-1 (200 μg cell homogenate, 0.0625 mg BCG, 0.02% formalin, 50 μg anti-PD-1) (G4). Five weeks post tumor induction all mice were euthanized, tumors extracted and evaluated pathologically and by immunohistochemistry. The combination group (G4) showed 10% more tumor necrosis, greater infiltration of PD-1+ cells and lower infiltration of TAMs, evidencing that the combination of ConvitVax and anti-PD-1 can improve the antitumor effect of the vaccine. Using a higher anti-PD-1 dose and administering each treatment at different times could further potentiate the effect of our therapy. Given the vaccine’s low cost and simple preparation, its use in combination with checkpoints or other target-specific compounds may lead to a highly effective personalized breast cancer immunotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.